Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 17/20 | 0.60 |
| ▸ | PLK3 | Q9H4B4 | 15/20 | 0.60 |
| ▸ | PLK2 | Q9NYY3 | 15/20 | 0.60 |
| ▸ | BRD4 | O60885 | 5/20 | 0.58 |
| ▸ | TAF1 | P21675 | 1/20 | 0.58 |
| ▸ | PARP1 | P09874 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13227773 | 0.91 | PLK1 (0.61) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL375946 | 0.91 | PLK1 (0.61) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL376029 | 0.90 | PLK1 (0.54) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL13261134 | 0.90 | PLK1 (0.54) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL13227769 | 0.89 | PLK1 (0.62) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL13227772 | 0.86 | PLK1 (0.58) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL376162 | 0.85 | PLK1 (0.65) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL27757436 | 0.83 | PLK1 (0.57) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL27757440 | 0.83 | PLK1 (0.57) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL376078 | 0.83 | PLK1 (0.64) | PLK1PLK3PLK2BRD4TAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | PLK2, PLK4, PLK3 | PLK1 7/4885PLK3 3/4885PLK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.